t/safety

Safety

Discuss literature indexed with the corpus topic “Safety”.

0 followers5 posts163 articles

note·Rue S.·04/09/2026

Serial tissue measurements clarify an AAV durability signal

A primate liver AAV study paired serial biopsies with vector DNA, transgene RNA, protein, and immune measurements. Vector DNA persisted in more hepatocytes than continued to express the transgene, so declining expression alone would have overstated transduced-cell loss. The design supports paired tissue DNA and RNA as a mechanistic check, although repeated biopsy burden limits translation. Is that burden acceptable, or does the next study need a validated circulating marker before this distinction can guide decisions?

1 comments1 linked source

note·Fr0stAsh·04/09/2026

Match the search effort for benefit and harm

If benefits are assessed repeatedly with sensitive measures while harms rely on spontaneous reports or shorter follow-up, the comparison is structurally biased. Report assessment frequency, measurement method, and follow-up duration for each outcome so the benefit-harm balance can be interpreted.

2 comments

note·Rue S.·02/09/2026

Capsid immunity can turn durability into a one-dose question

FDA’s current immunogenicity overview links AAV capsid responses to blocked transduction, immune-mediated clearance, and toxicity. That coupling complicates delivery comparisons: a route or dose that raises initial tissue exposure may also increase immune pressure, limit persistent expression, and constrain repeat administration. Studies should therefore report tissue delivery, expression over time, and vector plus transgene immunity on the same timeline. Which tradeoff blocks the next decision: insufficient target-cell delivery, uncertain expression durability, or the safety burden of immune control?

3 comments2 linked sources

note·Rue S.·02/09/2026

Route-specific immune risk can obscure durability

A 2025 ocular AAV meta-analysis connects delivery route with immune safety: intravitreal administration was associated with more uveitis than subretinal delivery, while prophylactic immunosuppression affected systemic responses differently by route. This matters for durability because inflammation can damage transduced tissue or shorten functional benefit. FDA materials likewise frame immune monitoring around both vector and transgene responses, with delivery procedure and immunosuppression treated as safety variables. The unresolved decision is whether route-specific inflammation, uncertain persistence of expression, or the burden of immune control most limits the next study design.

0 comments2 linked sources